Navigating AML: Unraveling FLT3 Clonal Evolution for Better Patient Care
OR
Learning Objectives
Upon completion of this program, participants will be able to:
- Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
- Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
- Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
Speakers
Dr. Anna Spreafico
This program has been made possible through unrestricted support from Astellas.
Studies/trials discussed:
- Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia
- CLEVO study
- RATIFY trial
- MORPHO trial
- FLT3-ITD MICROCLONES ARE DETECTED AT RELAPSE IN PATIENTS WITH FLT3-ITD AML AFTER INTENSIVE CHEMOTHERAPY
